Prana Biotech crash pinches rich listers

More than 75% of Prana Biotechnology stock has disintegrated this morning after the dual-listed company announced its phase 2b trial failed to reduce the symptoms of Alzheimer’s disease.

More than three quarters of the value in Prana Biotechnology (PBT) stock has disintegrated this morning after the dual-listed company announced its phase 2b trial failed to reduce the symptoms of Alzheimer’s disease.

Shares in the once-loved biotech have plunged 77% to 24 cents at 1100 AEDT – following a similar response in the US overnight – in response to the news.

Some of Australia’s wealthiest families have been caught up in the share price plunge with both the Smorgon and Lieberman families well-known stakeholders in the company.

Prana said that its drug PBT2 did not reach its primary endpoint to show a statistically significant reduction in the levels of beta-amyloid plaques in the brains of Alzheimer’s disease patients. Though the treatment did show an overall reduction, the company said there was also an “atypical reduction” from the placebo patients as well.

“Whilst not meeting our hopes, the result does not deter us from the future development of PBT2,” chief executive Geoffrey Kempler said.

The shocking share price reaction will hit a number of ‘rich list’ familes:The Smorgon family, worth about $2.64 billion, hold around one million shares in Prana, while the Liberman family (worth $2.1 billion) owns a private company that holds a 3.72% stake.

Prior to today, Prana had been one of the exceptional biotech stories: the stock had soared around 460% in the past year.

InvestSMART FORUM: Come and meet the team

We're loading up the van and going on tour from April to June, with events on the NSW central & north coast, the QLD mid-north coast and in Perth, Adelaide, Melbourne, Sydney and Canberra. Come and meet the team and take home simple strategies that you can use to build an investment portfolio to weather any storm. Book your spot here.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles